The Efficacy and Safety of Intravitreal Dexamethasone Implant as Anti-inflammatory Monotherapy in the Management of Tuberculosis-associated Intermediate Uveitis.

Abstract

AIM:

To study the long-term efficacy and safety of Ozurdex as anti-inflammatory monotherapy in the management of tuberculosis-associated intermediate uveitis (TBIU).

METHODS:

Retrospective analysis of eyes with TBIU that received Ozurdex as anti-inflammatory monotherapy with a follow-up of at least 1 year.

RESULTS:

13 eyes (2 pseudophakic) of 11 patients were included. Mean BCVA improved from 0.65 to 0.11 at 3 months (p = .0005) and remained 0.11 at 1 year. Mean central foveal thickness improved from 452.87µ to 187.25µ at 3 months (p = .0009) and 184.62µ at 1 year in 8 eyes with CME. Mean vitreous haze improved from 2.38 to 0.11 at 3 months with no recurrences at 1 year. Mean IOP increased from 13.15mmHg to 15.53mmHg (p = .013) at 2 months and reduced to 12.46mmHg by 1 year. None required antiglaucoma medication. One eye underwent cataract surgery. The mean follow-up was 18.4 months.

CONCLUSION:

Ozurdex is safe and efficacious in TBIU as anti-inflammatory monotherapy in conjunction with antitubercular therapy.

• Authors: Abhilasha Baharani, Raja Rami Reddy P, Pritam Manohar Patil
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 31 Issue 8 Pg. 1594-1602 (Oct 2023) ISSN: 1744-5078 [Electronic] England
• PMID: 34637663 (Publication Type: Journal Article)

Chemical References

• Glucocorticoids
• Drug Implants
• Anti-Inflammatory Agents
• Dexamethasone

Topics

• Humans
• Glucocorticoids (therapeutic use)
• Retrospective Studies
• Macular Edema (drug therapy)
• Drug Implants
• Anti-Inflammatory Agents (therapeutic use)
• Dexamethasone
• Intravitreal Injections
• Uveitis, Intermediate (complications, diagnosis, drug therapy)
• Tuberculosis
• Uveitis (complications, diagnosis, drug therapy)